About Vigeo therapeutics

About company

Vigeo Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic agents intended to treat an advanced malignant tumor that can effectively treat multiple types of cancer and improve the lives of patients. The company building a first-in-class drug discovery pipeline that reprograms the tumor immune microenvironment (TIME). They plan to commence multiple combination studies to evaluate VT1021 in combination with chemotherapies and/or anti-PD-1 antibodies. Vigeo Therapeutics was established in 2011 and is headquartered in Cambridge, Massachusetts, United States.